Cell Signaling Technology

Product Pathways - Cell Cycle / Checkpoint

CDK9 (C12F7) Rabbit mAb #2316

C-2k   CDC2L4   cyclin dependent kinase   P-TEFb   PITALRE   sc-8338   TAK  

No. Size Price
2316S 100 µl ( 10 western blots ) ¥3,250.00 现货查询 购买询价
2316T 20 µl ( 2 western blots ) ¥1,200.00 现货查询 购买询价
2316 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
W 1:1000 Human,Mouse,Rat,Hamster,Monkey,Bovine,Dog, Endogenous 42, 55 Rabbit IgG
IP 1:100
IHC-P 1:200
F 1:200
IF-IC 1:100
IHC-F 1:200

Species cross-reactivity is determined by western blot.

Applications Key: W=Western Blotting, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin), F=Flow Cytometry, IF-IC=Immunofluorescence (Immunocytochemistry), IHC-F=Immunohistochemistry (Frozen),

Specificity / Sensitivity

CDK9 (C12F7) Rabbit mAb detects endogenous levels of total CDK9 protein, both 42 kDa and 55 kDa isoforms. CDK9 (C12F7) Rabbit mAb能够检测内源性CDK9总蛋白,包括42kDa和55kDa亚型。

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CDK9. 该单克隆抗体是由合成的人源的针对CDK9蛋白羧基末端肽段免疫动物生产的。

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell types using CDK9 (C12F7) Rabbit mAb. Western blot 方法检测不同细胞提取物,使用的抗体为CDK9 (C12F7) Rabbit mAb。



Immunoprecipitation of CDK9 from HeLa cells using CDK9 (C12F7) Rabbit mAb. Western blot detection was performed using the same antibody. Lane 1 is 5% input. 从HeLa细胞中用CDK9 (C12F7) Rabbit mAb抗体免疫沉淀CDK9蛋白。随后用同一抗体进行western blot实验。泳道1为 5% input。

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using CDK9 (C12F7) Rabbit mAb in the presence of control peptide (left) or antigen specific peptide (right). 免疫组织化学方法检测石蜡包埋人类乳腺癌组织,使用的抗体为 CDK9 (C12F7) Rabbit mAb ,左图为对照多肽,右图为抗原特异性多肽。

Flow Cytometry

Flow Cytometry

Flow cytometric analysis of Jurkat cells using CDK9 (C12F7) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red). 流式细胞术分析Jurkat细胞,使用的抗体为CDK9 (C12F7) Rabbit mAb ,为蓝色。非特异性阴性对照抗体作为对比,为红色。



Confocal immunofluorescent analysis of HeLa cells using CDK9 (C12F7) Rabbit mAb (green). Actin filaments have been labeled with DY-555 phalloidin (red). 激光共聚焦免疫荧光方法检测HeLa细胞,使用的抗体为CDK9 (C12F7) Rabbit mAb ,呈绿色。肌动蛋白纤维用 DY-555 鬼笔环肽标记,呈红色。

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded K7M2 mouse syngeneic tumor using CDK9 (C12F7) Rabbit mAb. 免疫组织化学方法检测石蜡包埋K7M2小鼠自体肿瘤组织,使用的抗体为 CDK9 (C12F7) Rabbit mAb。

IHC-F (frozen)

IHC-F (frozen)

Immunohistochemical analysis of frozen SKOV-3 xenograft using CDK9 (C12F7) Rabbit mAb. 免疫组织化学方法检测SKOV-3细胞移植瘤冰冻切片,使用的抗体为CDK9 (C12F7) Rabbit mAb。


P-TEFb is a general transcription factor that regulates transcription elongation through phosphorylation of the C-terminal tail domain (CTD) of RNA polymerase II (RNAP II). The P-TEFb complex composed of a catalytic subunit, CDK9, and its regulatory cyclin partner, which can be cyclin T1, T2a, T2b or K (reviewed in 1,2). P-TEFb is recruited by the HIV Tat protein to allow transcriptional elongation, and subsequent replication of the viral genome. Inhibition of P-TEFb function therefore has potential for HIV therapy. 
 CDK9 exists as two isoforms, an abundant 42 kDa isoform, and a less abundant 55 kDa isoform, which contains an amino-terminal extension (3). The two forms likely have distinct purposes based on differential expression during lymphocyte activation (4,5) and on their localization within the nucleus (5). 
 Cyclin dependent kinases (CDKs) are activated in part by cyclin binding and by phosphorylation of a conserved threonine in the T-loop domain. Phosphorylation of CDK9 at the T-loop Thr186 by an unidentified nuclear kinase may be important in P-TEFb activation (6) and regulation of HIV transcription (7). Acetylation of CDK9 at Lys44 affects its ability to phosphorylate the RNAPII CTD (8). P-TEFb是一个普通的转录因子,它通过磷酸化RNA 聚合酶 II (RNAP II)C-末端尾巴结构域(CTD)来调节转录延伸。P-TEFb复合体由一个催化亚基,CDK9及其周期蛋白伴侣(可能是cyclin T1, T2a, T2b 或者 K)组成(回顾1,2)。P-TEFb被HIV Tat蛋白招募,促进转录延伸,随后病毒基因组开始复制。因此抑制P-TEFb的功能可以作为潜在的HIV疗法。CDK9以两种异构体的形式存在,一种是高丰度的42 kDa的异构体,一种是较低丰度的55 kDa的异构体并含有一个羧基末端延伸(3)。基于二者在淋巴细胞激活中的差异性表达(4,5)和核内定位的不同(5),两种异构体似乎有明显不同的作用。周期蛋白依赖性激酶(CDKs)的激活部分经由周期蛋白的结合与T-回路结构域中保守区苏氨酸的磷酸化。一种不明的核激酶介导的CDK9 186位苏氨酸磷酸化可能在P-TEFb激活和HIV转录调节中发挥重要作用(7)。CDK9在44位赖氨酸的乙酰化影响其磷酸化RNAPII CTD的能力(8)。

  1. Rice, A.P. and Herrmann, C.H. (2003) Curr HIV Res 1, 395-404.
  2. De Falco, G. and Giordano, A. (2002) Cancer Biol Ther 1, 342-7.
  3. Shore, S.M. et al. (2003) Gene 307, 175-82.
  4. Shore, S.M. et al. (2005) Gene 350, 51-8.
  5. Liu, H. and Herrmann, C.H. (2005) J Cell Physiol 203, 251-60.
  6. Chen, R. et al. (2004) J Biol Chem 279, 4153-60.
  7. Ammosova, T. et al. (2005) Retrovirology 2, 47.
  8. Fu, J. et al. (2007) Mol Cell Biol 27, 4641-51.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

U.S. Patent No. 5,675,063.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :